- Conditions
- ADHD, Autism Spectrum Disorder
- Interventions
- Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
- Drug
- Lead sponsor
- Daniel Coury
- Other
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Irvine, California • Los Angeles, California • Portland, Maine + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 214
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Stimulant Use (Diagnosis)
- Interventions
- Science to Service Laboratory
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Rockford, Illinois • Pawtucket, Rhode Island + 1 more
- Conditions
- Adolescent Idiopathic Scoliosis
- Interventions
- Caffeine Tablet, Placebo
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Adult Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Daytrana (methylphenidate patch)
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
- Interventions
- Solriamfetol 150 MG, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Bellflower, California • Chino, California + 33 more
- Conditions
- Attention Deficit Disorder With Hyperactivity, Epilepsy
- Interventions
- Extended Release Methylphenidate (OROS-Methylphenidate)
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- ADHD, Parenting
- Interventions
- Behavioral Parent Training, Extended release mixed amphetamine salts (MAS)
- Behavioral · Drug
- Lead sponsor
- University of Maryland, College Park
- Other
- Eligibility
- 3 Years to 65 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- College Park, Maryland
- Conditions
- ADHD
- Interventions
- Solriamfetol
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Dothan, Alabama • Maitland, Florida • Memphis, Tennessee
- Conditions
- Snoring
- Interventions
- Neostigmine Methylsulfate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Healthy
- Interventions
- Hallucinogens and psychoactive substances
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- 22q11 Deletion Syndrome
- Interventions
- NB-001, Placebo
- Drug · Other
- Lead sponsor
- Nobias Therapeutics, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- ADHD
- Interventions
- lisdexamfetamine
- Drug
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- aripiprazole, Sugar pill
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Major Depressive Disorder
- Interventions
- Amphetamine/dextroamphetamine, Placebo, Well-being therapy
- Drug · Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Substance Use Disorders, Methamphetamine Abuse
- Interventions
- Intranasal Methamphetamine
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride, Methylphenidate Hydrochloride, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Stimulants plus Lovaza, Stimulants plus placebo
- Dietary Supplement · Drug
- Lead sponsor
- Antonios Likourezos
- Other
- Eligibility
- 6 Years to 15 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Methamphetamine-dependence, Substance Abuse
- Interventions
- Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Smoking
- Interventions
- Study Agent, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Constipation by Outlet Obstruction
- Interventions
- Bisacodyl, Atropin
- Drug
- Lead sponsor
- The California Medical Innovations Institute, Inc.
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- San Diego, California • Augusta, Georgia
- Conditions
- Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Substance Abuse
- Interventions
- Adderall
- Drug
- Lead sponsor
- Jeffrey Newcorn
- Other
- Eligibility
- 7 Years to 12 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine 80 MG
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Enhanced Recovery After Surgery in a Pediatric Population
- Interventions
- Caffeine citrate 15mg/kg, 0.9% Sodium Citrate
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois